Published in Haematol Blood Transfus on January 01, 1987
Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood (1994) 2.78
Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. The German Aplastic Anemia Study Group. N Engl J Med (1991) 2.40
Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia (2009) 2.30
TIF1gamma, a novel member of the transcriptional intermediary factor 1 family. Oncogene (1999) 2.05
Congenital dyserythropoietic anemia with karyorrhexis and multinuclearity of erythroblasts. Helv Med Acta (1968) 2.02
Diagnostic workup of patients with acquired von Willebrand syndrome: a retrospective single-centre cohort study. J Thromb Haemost (2008) 1.80
Peripheral blood tyrosinase messenger RNA detection and survival in malignant melanoma. J Natl Cancer Inst (1996) 1.79
Aetiology and clinical significance of thrombocytosis: analysis of 732 patients with an elevated platelet count. J Intern Med (1999) 1.79
Prethymic phenotype and genotype of pre-T (CD7+/ER-)-cell leukemia and its clinical significance within adult acute lymphoblastic leukemia. Blood (1989) 1.74
High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Blood (1997) 1.74
Treatment of Adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL). Hematol Oncol Clin North Am (2000) 1.69
Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood (1988) 1.69
Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol (2004) 1.62
Analysis of factors contributing to higher erythropoietin levels in patients with chronic liver disease. Scand J Gastroenterol (2004) 1.60
Host-specific interleukin-2-secreting donor T-cell precursors as predictors of acute graft-versus-host disease in bone marrow transplantation between HLA-identical siblings. N Engl J Med (1992) 1.59
Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies. Br J Cancer (2011) 1.53
Characteristics of Hodgkin's disease-derived cell lines. Cancer Treat Rep (1982) 1.51
Low incidence of invasive fungal infections after bone marrow transplantation in patients receiving amphotericin B inhalations during neutropenia. Ann Hematol (1994) 1.51
SETBP1 mutation analysis in 944 patients with MDS and AML. Leukemia (2013) 1.50
[Severe tetraparesis as the first manifestation of a chronic lymphatic leukemia]. Dtsch Med Wochenschr (1992) 1.39
Changes in erythroid progenitor cell and accessory cell compartments in patients with myelodysplastic syndromes during treatment with all-trans retinoic acid and haemopoietic growth factors. Br J Haematol (1995) 1.39
Streptococcal bacteremia in adult patients with leukemia undergoing aggressive chemotherapy. A review of 55 cases. Infection (1990) 1.39
SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications. Leukemia (2011) 1.38
High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia. Ann Oncol (1998) 1.38
[Fall Congress for Integrative Medicine--model for the future]. Dtsch Med Wochenschr (2009) 1.38
Histone acetylation modifiers in the pathogenesis of malignant disease. Mol Med (2000) 1.36
Structural analysis of the deoxycytidine kinase gene in patients with acute myeloid leukemia and resistance to cytosine arabinoside. Leukemia (1994) 1.32
Congenital dyserythropoietic anaemia, types I and II: aberrant pattern of erythrocyte membrane proteins in CDA II, as revealed by two-dimensional polyacrylamide gel electrophoresis. Br J Haematol (1977) 1.30
A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia (2004) 1.28
Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study. Leukemia (2012) 1.27
Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood (1996) 1.26
Graft-versus-leukemia effects in T lineage and B lineage acute lymphoblastic leukemia. Bone Marrow Transplant (1998) 1.25
PIC-1/SUMO-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. Mol Cell Biol (1999) 1.25
Extrarenal erythropoietin production by macrophages. Blood (1982) 1.24
Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia. Leukemia (2012) 1.23
Clinical and molecular characterization of early T-cell precursor leukemia: a high-risk subgroup in adult T-ALL with a high frequency of FLT3 mutations. Blood Cancer J (2012) 1.22
The human C3a receptor is expressed on neutrophils and monocytes, but not on B or T lymphocytes. J Exp Med (1997) 1.22
High levels of thrombopoietin in sera of patients with essential thrombocythemia: cause or consequence of abnormal platelet production? Ann Hematol (1998) 1.21
Consensus conference on European preparedness for haematological and other medical management of mass radiation accidents. Ann Hematol (2006) 1.21
Marrow fibrosis predicts early fatal marrow failure in patients with myelodysplastic syndromes. Leukemia (2007) 1.21
Aberrant methylation and impaired expression of the p15(INK4b) cell cycle regulatory gene in chronic myelomonocytic leukemia (CMML). Leukemia (2003) 1.19
Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment. Leukemia (2003) 1.16
Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group. Blood (1993) 1.16
Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia. Ann Hematol (2004) 1.15
Tumor necrosis factor induces proliferation of neoplastic B cells from chronic lymphocytic leukemia. Blood (1989) 1.14
Electron and light microscopic study of the erythroblasts of patients with congenital dyserythropoietic anemia. Blood (1971) 1.14
Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism. Blood (2000) 1.14
Defective in vitro growth of the hemopoietic progenitor cells in the acquired immunodeficiency syndrome. J Clin Invest (1987) 1.13
Identification of high-risk patients with aplastic anaemia in selection for allogeneic 0one-marrow transplantation. Lancet (1976) 1.10
Quantitative determination of lentiviral vector particle numbers by real-time PCR. Biotechniques (2001) 1.09
Emergence of CD52-, phosphatidylinositolglycan-anchor-deficient T lymphocytes after in vivo application of Campath-1H for refractory B-cell non-Hodgkin lymphoma. Blood (1995) 1.09
Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML-BFM and DCOG study groups. Leukemia (2011) 1.07
In vivo/ex vivo T cell depletion for GVHD prophylaxis influences onset and course of active cytomegalovirus infection and disease after BMT. Bone Marrow Transplant (1995) 1.06
Metastatic malignant ameloblastoma responding to chemotherapy with paclitaxel and carboplatin. Ann Oncol (2001) 1.06
Antimicrobial susceptibility of viridans group streptococci isolated from patients with acute leukemia receiving ofloxacin for antibacterial prophylaxis. Infection (1990) 1.06
Effect of recombinant interferons alpha and gamma on human bone marrow-derived megakaryocytic progenitor cells. Blood (1987) 1.06
Mutation analysis of the DNA-damage checkpoint gene CHK2 in myelodysplastic syndromes and acute myeloid leukemias. Leuk Res (2001) 1.05
Monitoring minimal residual disease by quantification of genomic chromosomal breakpoint sequences in acute leukemias with MLL aberrations. Leukemia (2006) 1.05
T lymphocyte control of human eosinophilic granulopoiesis. Clonal analysis in an idiopathic hypereosinophilic syndrome. J Immunol (1987) 1.05
Prognostic impact of in vivo soluble cell adhesion molecules in metastatic renal cell carcinoma. Br J Cancer (1999) 1.03
[Congenital dyserythropoietic anemia]. Arch Klin Med (1968) 1.03
Development of the glycosylphosphatitylinositol-anchoring defect characteristic for paroxysmal nocturnal hemoglobinuria in patients with aplastic anemia. Blood (1994) 1.02
Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia. Leukemia (2012) 1.02
In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin's lymphomas using combinations of established cytotoxic drugs with bendamustine. Haematologica (2001) 1.01
Recombinant factor VIII expression in hematopoietic cells following lentiviral transduction. Gene Ther (2003) 1.01
Molecular heterogeneity of sporadic adult Burkitt-type leukemia/lymphoma as revealed by PCR and cytogenetics: correlation with morphology, immunology and clinical features. Leukemia (2005) 1.01
Clonal analysis of myelodysplastic syndromes: evidence of multipotent stem cell origin. Blood (1989) 1.00
dic(9;20): a new recurrent chromosome abnormality in adult acute lymphoblastic leukemia. Genes Chromosomes Cancer (1995) 1.00
Stable RNA interference (RNAi) as an option for anti-bcr-abl therapy. Gene Ther (2005) 1.00
Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study. Ann Oncol (2004) 1.00
Detection of antisense and ribozyme accessible sites on native mRNAs: application to NCOA3 mRNA. Mol Ther (2001) 1.00
Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer. J Clin Oncol (1999) 1.00
Production of colony-stimulating factors by Hodgkin cell lines. Int J Cancer (1983) 1.00
Antioxidative treatment prevents activation of death-receptor- and mitochondrion-dependent apoptosis in the hearts of diabetic rats. Diabetologia (2004) 0.99
Remarkable leukemogenic potency and quality of a constitutively active neurotrophin receptor, deltaTrkA. Leukemia (2007) 0.99
Chemotherapy compared with bone marrow transplantation for adults with acute lymphoblastic leukemia in first remission. Ann Intern Med (1991) 0.99
Lactate dehydrogenase-release assay: a reliable, nonradioactive technique for analysis of cytotoxic lymphocyte-mediated lytic activity against blasts from acute myelocytic leukemia. Ann Hematol (1995) 0.99
Changing incidence and survival in patients with aids-related non-Hodgkin's lymphomas in the era of highly active antiretroviral therapy (HAART). Leuk Lymphoma (2001) 0.98
High risk of streptococcal septicemia after high dose cytosine arabinoside treatment for acute myelogenous leukemia. Klin Wochenschr (1987) 0.98
Chronic myelogenous leukemia in blast crisis: retrospective analysis of prognostic factors in 90 patients. Ann Hematol (1996) 0.98
Human fetal and adult chondrocytes. Effect of insulinlike growth factors I and II, insulin, and growth hormone on clonal growth. J Clin Invest (1986) 0.98